HDAC9 and colorectal carcinoma: Therapy interface: in vivo, butyrate accelerates CD8+ T-cell infiltration and synergizes with anti-PD-1 in CRC models, consistent with SCFAs’ HDAC-dependent T-cell programming [14, 91].